Publisher’s Observe: MDPI stays neutral regarding jurisdictional claims in published maps and institutional affiliations. Even further therapy possibilities such as bDMARDs, tsDMARDs, biosimilars or blend therapy can be found when csDMARDs are ineffective or badly tolerated. bDMARDs are a more moderen option for the therapy of RA and provide a https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/